Safety, pharmacokinetics, and pharmacodynamics of a next‐generation subcutaneously administered coagulation factor IX variant, dalcinonacog alfa, in previously treated hemophilia B patients - You, Chur Woo; Hong, Seung‐Beom; Kim, Suyeong; Shin, Ho‐Jin; Kim, Jin Seok; Han, Jung Woo; Kim, Soo‐Jeong; Kim, Do Young; Lee, Martin; Levy, Howard (Journal of thrombosis and haemostasis, 2021)
Keywords: Adolescent; Adult; Aged; Antiplatelet therapy; Bioavailability; blood coagulation; Blood Coagulation Tests; Child; Coagulation factor IX; Coagulation factors; Factor IX; Factor IX deficiency; Half-Life; Hematology; Hemophilia; Hemophilia A; hemophilia B; Hemophilia B - diagnosis; Hemophilia B - drug therapy; Humans; injections; Intravenous administration; Male; Middle Aged; Pharmacodynamics; Pharmacokinetics; Prophylaxis; Recombinant Proteins; Safety; subcutaneous; Young Adult; injections; subcutaneous; recombinant proteins; factor IX; blood coagulation; hemophilia B